Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: Results from an open-label study

Drug Research

Volumn 63, Issue 12, 2013, Pages 639-643

  Takanashi, M ^a   Shimo, Y ^a   Hatano, T ^a   Oyama, G ^a   Hattori, N ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

extended release; immediate release; Parkinson's disease; pramipexole; UPDRS part III

Indexed keywords

PRAMIPEXOLE;

ADULT; AGED; ARTICLE; CAREGIVER; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DAYTIME SOMNOLENCE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG SUBSTITUTION; EXTENDED RELEASE TABLET FORMULATION; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; IMMEDIATE RELEASE TABLET FORMULATION; MALE; MIDDLE AGED; MOTOR DYSFUNCTION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NIGHT SLEEP; OPEN STUDY; PARKINSON DISEASE; PATIENT PREFERENCE; PHYSICIAN; QUALITY OF LIFE; SLEEP DISORDER; SUSTAINED DRUG RELEASE; TABLET FORMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84890968987     PISSN: 21949379     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0033-1351257     Document Type: Article

References (27)

1. Holloway R. G., Shoulson I., Fahn S. et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol: 2004; 61 1044 1053
2. Lieberman A., Ranhosky A., Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology: 1997; 49 162 168
3. Mizuno Y., Yanagisawa N., Kuno S. et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord: 2003; 18 1149 1156
4. Möller J. C., Oertel W. H., Köster J. et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord: 2005; 20 602 610
5. Pinter M. M., Pogarell O., Oertel W. H. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry: 1999; 66 436 441
6. Könen-Bergmann M., Haertter S., Schepers C. A multiple rising-dose bioequivalence phase 1 study with a pramipexole extended release (ER) formulation. Eur J Neurol: 2008; 15 97 98
7. Sha K., Takizawa A., Kanada S. et al. Phase I clinical study of pramipexole long acting tablets - Bioavailability of long acting formulation relative to immediate release formulation in healthy subjects. Clinical Pharmacology and Therapy: 2011; 21 159 171 (in Japanese)
8. Mizuno Y., Yamamoto M., Kuno S. et al. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: A double-blind, randomized trial. Clin Neuropharmacol: 2012; 35 174 181
9. Hauser R. A., Schapira A. H., Rascol O. et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord: 2010; 25 2542 2549
10. Schapira A. H., Barone P., Hauser R. A. et al. Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial. Neurology: 2011; 77 767 774
11. Poewe W., Rascol O., Barone P. et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology: 2011; 77 759 766
12. Grosset D., Antonini A., Canesi M. et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord: 2009; 24 826 832
13. Nyholm D., Askmark H., Gomes-Trolin C. et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol: 2003; 26 156 163
14. Devos D. for the French DUODOPA Study Group Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord: 2009; 24 993 1000
15. Chaudhuri K. R., Pal S., DiMarco A. et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry: 2002; 73 629 635
16. Goetz C. G., Tilley B. C., Shaftman S. R. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord: 2008; 23 2129 2170
17. Trenkwalder C., Kohnen R., Högl B. et al. Parkinson's disease sleep scale - validation of the revised version PDSS-2. Mov Disord: 2011; 26 644 652
18. Trenkwalder C., Kies B., Rudzinska M. et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord: 2011; 26 90 99
19. Kohmoto J., Ohbu S., Nagaoka M. et al. Validation of the Japanese version of the Parkinson's disease questionnaire. Clinical Neurology: 2003; 43 71 76 (in Japanese)
20. Takegami M., Suzukamo Y., Wakita T. et al. Development of a Japanese version of the Epworth Sleepiness Scale (JESS) based on item response theory. Sleep Med: 2009; 10 556 565
21. Rascol O., Barone P., Hauser R. A. et al. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. Mov Disord: 2010; 25 2326 2332
22. Stocchi F., Barbato L., Nordera G. et al. Sleep disorders in Parkinson's disease. J Neurol: 1998; 245 01 S15 S18
23. Giladi N., Fichtner A., Poewe W. et al. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. J Neural Transm: 2010; 117 1395 1399
24. Poewe W. H., Rascol O., Quinn N. et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol: 2007; 6 513 520
25. Jenkinson C., Fitzpatrick R., Peto V. et al. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing: 1997; 26 353 357
26. Carod-Artal F. J., Martinez-Martin P., Vargas A. P. Independent validation of SCOPA-psychosocial and metric properties of the PDQ-39 Brazilian version. Mov Disord: 2007; 22 91 98
27. Schapira A. H., Barone P., Hauser R. A. et al. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol: 2013; 20 50 56